Trial · NCT06004050
A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema
NCT06004050, Phase 3, Completed, LEO Pharma
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema. Trials, record NCT06004050. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06004050
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema
- NCT number
- NCT06004050
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 362 participants, actual
- Lead sponsor
- LEO Pharma
- Conditions
- Chronic Hand Eczema
- Interventions
- Delgocitinib, Vehicle cream
- First posted
- 2023-08-22
- Last updated
- 2025-09-25
Source ClinicalTrials.gov
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Investigator Global Assessment for Chronic Hand Eczema Score (IGA-CHE TS) at Week 16 | Week 16 | The IGA-CHE score ranges from 0 (clear) to 4 (severe). Treatment response is defined as a score of 0 or 1. |
| Secondary | Hand Eczema Severity Index (HECSI)-90 at Week 16 | Week 16 | Defined as at least a 90% improvement in HECSI score from baseline. |
| Secondary | HECSI-75 at Week 16 | Week 16 | Defined as at least a 75% improvement in HECSI score from baseline. |
| Secondary | Percentage Change in HECSI Score From Baseline to Week 16 | Baseline and Week 16 | HECSI score is used to rate the severity of hand eczema and ranges from 0 (lowest possible score) to 360 (highest possible score). |
| Secondary | Number of Participants With Reduction of Hand Eczema Symptom Diary (HESD) Itch Score by ≥4 Points From Baseline at Week 16 | Baseline and Week 16 | |
| Secondary | Number of Participants With Reduction of HESD Score by ≥4 Points From Baseline at Week 16 | Baseline and Week 16 | |
| Secondary | Number of Participants With Reduction of HESD Pain Score by ≥4 Points From Baseline at Week 16 | Baseline and Week 16 | |
| Secondary | Change in Dermatology Life Quality Index (DLQI) Score From Baseline to Week 16 | Baseline and Week 16 | |
| Secondary | Change in HESD Score From Baseline to Week 16 | Baseline and Week 16 | |
| Secondary | Change in HESD Itch Score From Baseline to Week 16 | Baseline and Week 16 |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06004050
GET https://conductscience.org/api/trials/v1/NCT06004050/registered